Arkema S.A.: Q2 2026 EBITDA of EUR 390.9m Beat Consensus by About 8% at a 16.1% Margin, but 2.9-Times Leverage Leaves EUR 58.05 Far Above the EUR 32 to EUR 36 Conservative Buy Zone

Composition matters here. Adhesive Solutions booked EUR 735.4 million of Q2 sales and EUR 111.0 million of EBITDA, on organic growth of 3.8% and a 15.1% margin. Advanced Materials turned EUR 872.0 million of sales into EUR 162.9 million of EBITDA, but that EBITDA fell 13.2% year on year and the margin contracted to 18.7% from 20.9%. Coating Solutions was the earnings standout: EUR 422.4 million of sales generated EUR 78.2 million of EBITDA, up 52.9%, lifting the margin to 18.5% from 12.7%. Primary Materials, still roughly 16% of group sales, earned EUR 57.7 million of EBITDA on EUR 389.3 million of sales.

The same quarter shows why the headline 5.1% price effect should not be read as proof that Arkema suddenly acquired exceptional pricing power. Primary Materials pricing was up 16.0%, principally because acrylic-monomer pricing reacted to Middle East disruptions; volumes there were down 9.7%. In Coating Solutions, the reported 4.7% price effect carried a negative mechanical impact of about 3.5 percentage points from the conversion of certain activities to manufacturing agreements, so the economically relevant price/mix signal was stronger than the raw number but also distorted by business-model changes. Adhesives had a cleaner 3.4% price effect with positive mix. Read at group level, much of the pricing is pass-through, scarcity pricing or mix rather than a permanent increase in willingness to pay.

The “Middle East difficulty” cited around Q2 needs a tighter definition. Arkema disclosed no damaged plant of its own in the Middle East and no single asset outage. Its Q2 materials put the weakness in the Performance Additives part of Advanced Materials: softer demand in some refining and fertilizer applications, arriving alongside sharply higher sulfur input costs. One relevant product family is thiochemicals, among them dimethyl disulfide, or DMDS, used to activate hydrotreating catalysts in refineries and increasingly in biofuel production. Arkema had started additional U.S. DMDS capacity in 2025. The company disclosure gives no evidence that this new unit itself was impaired or was the source of the Q2 problem.

The size of that Middle East headwind is not disclosed. Advanced Materials EBITDA declined EUR 24.7 million year on year in Q2, while Arkema described High Performance Polymers as broadly stable and identified Performance Additives and some fluorospecialty effects as the weaker areas. From that it is reasonable to infer that the refining/fertilizer/sulfur shock accounted for a meaningful fraction of the segment decline, but assigning a specific euro figure would be false precision. The available evidence points primarily to a cyclical and geopolitical demand/input-cost shock rather than a structural impairment of an Arkema asset. A prolonged regional conflict or structurally weaker refining economics could make it last longer.

Management's full-year 2026 framework stays modest. As of the latest earnings disclosure, Arkema expected EBITDA to be slightly higher than 2025 at constant exchange rates. Large growth projects were expected to contribute roughly EUR 50 million of additional EBITDA during 2026 versus 2025, after approximately EUR 25 million in the first half, and management targeted about EUR 90 million of fixed- and variable-cost savings. Capital expenditure was to be limited to EUR 600 million. Through September 10 I found no later results release that superseded the July 30 outlook; the Euronext and company notices that followed were principally share-capital and own-share disclosures. That leaves the Q2 guidance as the operative public guidance at the research date.

Those numbers matter because 2025 was weak. Full-year sales came in at EUR 9.068 billion and company-defined EBITDA at EUR 1.251 billion, a 13.8% margin. Demand stayed soft in the United States and Europe, while Asia held up better. Arkema did produce about EUR 60 million of incremental EBITDA from major projects compared with 2024, but management acknowledged that the contribution fell below the original expectation even though the projects were described as being delivered to schedule and budget. Recurring cash flow was EUR 464 million.

Arkema therefore sits in an unusual middle ground. It no longer deserves the simple commodity-chemical label attached to its predecessor portfolio. Bostik adhesives, specialty polyamides, PVDF, polyimide films, high-performance coating resins and additives carry considerably better technical differentiation, qualification barriers and customer intimacy. Yet the earnings record has not reached the stability of the highest-quality formulation peers. Advanced Materials can still suffer double-digit EBITDA changes on modest sales movements, Primary Materials preserves explicit commodity-spread exposure, and acquisition-funded transformation has left leverage at 2.9 times last-twelve-month EBITDA when net debt and hybrid bonds are combined.

At EUR 58.05, the equity market appears to acknowledge those shortcomings. The August share count gives equity value of about EUR 4.42 billion. Add EUR 3.605 billion of net debt plus hybrid bonds at June 30 and the analytical enterprise value, deliberately conservative, comes to approximately EUR 8.02 billion. Against the EUR 1.259 billion FY2026 EBITDA consensus published by Arkema around Q2, the stock is valued at roughly 6.4 times enterprise value to company-defined EBITDA. The same consensus had adjusted EPS of EUR 4.65, implying about 12.5 times adjusted forward earnings. The EUR 3.60 dividend corresponds to a trailing indicated yield of approximately 6.2% at the September 9 price.

These are discounted-specialty valuation levels, not premium-specialty ones. The discount is not irrational. Sika, the clearest formulation-and-adhesives quality benchmark, entered 2026 after a difficult construction year, yet still reported a materially higher EBITDA margin and targeted a 19.5–20.0% margin for 2026. Arkema can reach margins above 18% in selected platforms, as Coatings did in Q2, but it has not established that level for the group through a full cycle.

The market narrative, then, is a contest between transition and cyclicality. Read optimistically: the heavy portfolio work is largely finished, new PA11, PVDF, polyimide and adhesive capacity is becoming productive, structural cost reduction is arriving at the same time as a possible volume trough, and 2025's EUR 1.251 billion EBITDA understates normal earnings. Read skeptically: the group remains sensitive to the same industrial variables that caused the downturn, Q2 pricing was unusually supported by raw-material and geopolitical conditions, the balance sheet has less room after the acquisition and capex phase, and premium-specialty margins are still something Arkema has to prove rather than something investors should capitalize in advance.

My qualitative portrait is company in transition. Late-stage transition, not embryonic: the portfolio is already 85% Specialty Materials, but the next phase has to prove that the new portfolio can compound cash flow and returns on invested capital with less cycle dependence. The investment question has moved from “can management change the portfolio?” to “did management buy and build assets that will earn sufficiently high returns after the cycle, financing costs and maintenance capital are included?”

Vertical history, financial record, and capital-market narrative

Arkema's corporate birth reads as an industrial carve-out rather than a conventional entrepreneurial founding. The chemical assets had roots inside Total, Elf Aquitaine, Atochem and Atofina, and in preparation for separation the Arkema perimeter was organized within Total ahead of the public listing. Arkema S.A. itself took the Arkema name in April 2006, and its shares began trading on Euronext Paris on May 18, 2006.

The listing path matters because standard IPO language produces the wrong answer here. Arkema's prospectus stated that no shares were being offered for subscription. The separation distributed Arkema equity to the relevant Total/Elf shareholder base and established an independently traded company; it did not sell new shares to raise primary IPO proceeds. So there is no meaningful conventional “IPO issue price” or “capital raised” to quote. The correct capital-markets event was a spin-off/direct admission whose value was subsequently established by trading.

That starting structure explains the first strategic problem. Total had reason to separate a collection of chemicals whose capital intensity, cyclicality and strategic logic differed from oil and gas. Arkema inherited businesses; it did not design a clean specialty portfolio from scratch. The company itself now describes the 2006 perimeter as predominantly European and commodity-oriented, with Specialty Materials accounting for only 36% of revenue. The first decade of independent life went into deciding what Arkema should cease to be.

The first stage, from the separation through the early 2010s, was portfolio triage and independent operating discipline. The inherited commodity-heavy chemical portfolio offered scale but exposed earnings to feedstocks, European fixed costs and commodity spreads. Management progressively moved capital toward higher-value acrylics, specialty additives, technical polymers and downstream formulation while preparing exits from structurally less attractive assets. Selling the vinyl-products business was the clearest symbolic break: out went a large, cyclical and capital-intensive activity, and the specialty ambition gained credibility. Arkema's later twenty-year retrospective puts this divest-and-reinvest process at the center of the group's transformation.

The second stage crystallized around Bostik. Buying the adhesives company in 2015 gave Arkema what upstream specialty chemicals often lack: a large formulation business sitting close to the customer's production line or construction site. Bostik became the nucleus of Adhesive Solutions, and subsequent bolt-ons, including sealant and formulation assets, widened the product set and the geographic network. Arkema describes Bostik as the transaction that created its Adhesive Solutions pillar, and lists Coatex, Sartomer, Den Braven and later Ashland's performance-adhesive activities among the acquisitions that changed the portfolio.

This was more than diversification. An adhesive can be a small fraction of a customer's finished-product cost while being critical to bond strength, production speed, recyclability, weight or product failure. Those economics support better pricing and retention than selling an undifferentiated ton of monomer. Hence the strategic choice: move downstream toward formulation without abandoning Arkema's chemistry base. Bostik did not turn Arkema into Sika; it gave Arkema one business with increasingly Sika-like economics alongside more materials-intensive platforms.

The third stage, spanning roughly the late 2010s through 2022, accelerated the specialty conversion. ArrMaz expanded performance additives used in fertilizer, mining and industrial applications. Out went PMMA, another sizeable polymer exposure that management did not regard as core to the targeted specialty architecture. Ashland's performance-adhesives assets deepened Bostik in high-performance industrial adhesives. Arkema was at the same time investing directly in its own high-value polymer technologies, not relying entirely on acquisitions.

The most visible organic example was the new bio-based polyamide-11 platform in Singapore. Arkema says it invested roughly EUR 500 million over 2018–2021 in the Singapore project and related capacity. Strategically that commitment counts, because PA11 is one of Arkema's clearest proprietary material franchises, sold into applications where chemical resistance, flexibility, light weight and durability matter. The platform also shifts capacity toward Asia, which addresses another inheritance from 2006: excessive European geographic concentration. Arkema now says sales are distributed at roughly one-third in each of the three major world regions.

At first the financial cycle made this strategy look exceptionally powerful. Pandemic supply constraints and the 2021–2022 industrial rebound let specialty chemical companies reprice aggressively. Arkema's group EBITDA moved well above pre-pandemic levels and peaked above EUR 2 billion in 2022. Real portfolio improvement and cyclical scarcity arrived together. Investors who attributed all of the margin increase to permanent business-quality improvement were effectively capitalizing a favorable spread cycle. The subsequent normalization exposed how much of the peak had been cyclical: Arkema's own later disclosures show EBITDA back at EUR 1.251 billion in 2025.

This distinction matters for interpreting management's long record. Thierry Le Hénaff has led Arkema across essentially the entire independent-company period. Portfolio transformation is the durable achievement. Normalized return on the capital spent to achieve it is the less-settled question. Acquisitions and large organic projects replaced disposed earnings, increased technical differentiation and widened the geographic footprint, but they also left substantial goodwill, acquired intangibles and debt. What management now needs is for cash generation from those assets to catch up with the capital committed.

The fourth stage, beginning around 2023 and extending through the present, is best called digestion and proof. Demand weakened across European construction and industrial markets, inventories normalized, and the European chemical complex faced structurally high energy and regulatory costs. Arkema continued its transformation anyway, with PI Advanced Materials, flexible-packaging adhesive assets and a slate of organic projects in PA11, PVDF and specialty fluorochemistry. The timing made for a difficult accounting picture, with capital expenditures and acquisition financing arriving before the full earnings contribution while the underlying cycle weakened.

The European backdrop is unusually harsh. Industry data from Cefic, cited by the Financial Times, showed confirmed investment in European chemical capacity falling by more than 80% in 2025 while announced closures increased sharply; Cefic attributed the pressure to energy costs, regulation and import competition among other factors. Arkema is better insulated than a basic-chemicals producer, since much of its portfolio is formulated or high-performance. It still owns European chemical plants and sells to European industrial customers, so industry-wide fixed-cost pressure reaches it both directly and through those customers.

Arkema's response has two legs. Portfolio quality is the first: sell products for which the customer's qualification, formulation or performance need matters more than the molecule's spot price. The second is continuous cost removal from the inherited manufacturing base. In H1 2026 Arkema reported approximately 365 fewer full-time-equivalent positions and maintained a program intended to offset fixed-cost inflation; for the full year it targeted roughly EUR 90 million of fixed- and variable-cost savings versus 2025. That matters economically because weak volume leaves plant utilisation unable to do the margin work by itself.

A selected group financial record illustrates the cycle. The figures below are reported group figures, not a synthetic like-for-like segment series. Acquisitions, disposals and segment-perimeter changes mean they should be used to understand the earnings arc, not to infer organic CAGR.

Sources: Arkema annual-result history and the latest FY2025/H1 2026 disclosures. Historical figures are rounded because the purpose is the cycle comparison, while 2025–2026 figures use the current disclosures.

The business reason behind the arc is more useful than the CAGR. 2020 combined pandemic demand pressure with a pre-boom price environment. 2021–2022 added reopening, product scarcity, aggressive price pass-through and strong industrial demand. By 2023–2025, inventories had normalized, European manufacturing had weakened, and pricing no longer expanded enough to offset lower volumes. At the same time, the transformed company carried a larger specialty contribution than it had before the boom. The result: EBITDA well below the 2022 peak, yet still supported by businesses that did not exist in comparable form a decade earlier.

Portfolio changes make segment history especially treacherous. For 2026 Adhesive Solutions, Advanced Materials, Coating Solutions and Primary Materials I use Arkema's own restated 2025 comparatives. I do not splice older “High Performance Materials,” legacy Bostik or pre-divestiture segment figures into those series. The multi-year figures above are group reported numbers, explicitly not presented as like-for-like segment growth.

Cash quality has likewise become a more important issue as growth capex and M&A have accumulated. FY2025 recurring cash flow was EUR 464 million. H1 2026 recurring cash flow was negative EUR 17 million and free cash flow negative EUR 40 million, although Q2 itself recovered to EUR 78.3 million of recurring cash flow and EUR 67.7 million of free cash flow. Working capital at June 30 represented 15.8% of annualized sales versus 17.0% a year earlier, so the H1 cash deficit was not evidence of a working-capital blowout. Seasonality, capex and the weaker profit base matter.

The balance sheet is the principal reason the next earnings recovery matters more than the last acquisition. Net debt plus hybrid bonds stood at EUR 3.605 billion at June 30, 2026, equivalent to 2.9 times last-twelve-month EBITDA by Arkema's measure. The EUR 3.60 per-share annual dividend consumed approximately EUR 272 million of cash in May. Leverage at this level is manageable for a diversified profitable chemical group, but it limits freedom to absorb another severe cycle, fund a large acquisition and preserve shareholder distributions simultaneously.

The capital-market narrative has followed these stages. In the early independent period Arkema traded primarily as a European cyclical chemical restructuring story. The disposals and the Bostik acquisition gradually earned it a specialty-materials identity, and the 2021–2022 earnings surge temporarily added a scarcity-pricing narrative on top. Then came the derating, reflecting weaker European demand, lower normalized margins, higher rates and concern that acquisition/capex spending had outrun near-term cash generation. The present valuation says the market has not awarded Arkema the full premium-specialty label.

The current share price also sits inside a broad recent trading range, not at a euphoric extreme: market data around September 9 put the preceding 52-week range at roughly EUR 48.30 to EUR 67.05, with the latest close at EUR 58.05. A price range by itself says nothing about intrinsic value, but it confirms that Q2's earnings beat has not produced a runaway re-rating.

One last governance detail belongs in the vertical story, because it affects who can influence that strategy. Arkema is not controlled by a founding family or a separate super-voting share class. Employee shareholders owned about 9.7% of the capital at the end of 2025, and the company planned another employee capital increase in the second half of 2026. Double voting for long-registered shares gives patient registered holders greater voting influence, while the chairman and chief executive roles remain combined under Thierry Le Hénaff. That is a governance concentration, although it sits alongside a long public-company record rather than founder control.

Business model, moat, governance, and industry cycle

Arkema reports three Specialty Materials segments plus Primary Materials. The specialty platforms are Adhesive Solutions, Advanced Materials and Coating Solutions. Primary Materials holds what is left, the upstream/cyclical activities that management has not classified as part of its specialty-growth platforms. Arkema's strategy materials organize the company explicitly around bonding and assembly, lightweighting and strengthening, and coating/protection technologies, all of it resting on polymerization, formulation and application know-how.

The Q2 2026 earnings mix shows where the economics currently sit.

Arkema's Q2 disclosure. Percentages are company-rounded segment mix figures.

Advanced Materials is still the largest earnings engine. But Q2 warns against equating “advanced” with “defensive.” High Performance Polymers and Performance Additives together produced EUR 872 million of sales, which the presentation split into approximately EUR 479 million of High Performance Polymers and EUR 393 million of Performance Additives. High-performance areas such as batteries, electronics, three-dimensional printing and polyimide materials held up, while refinery/fertilizer-sensitive Performance Additives suffered. The segment's high margin reflects technical value, but it stays sensitive to mix and utilization.

Adhesive Solutions is economically different. Bostik sells formulated bonding solutions into construction, packaging, durable goods and industrial assembly. In Q2 aerospace, consumer electronics and industrial assembly ran stronger, construction and packaging volumes weaker. Organic sales nevertheless rose 3.8%: a 3.4% positive price effect plus 0.4% volume growth. At 15.1%, the margin remains below Sika-like levels, which leaves both an opportunity and a warning. Mix, integration and cost improvement can expand earnings if they succeed, but the segment has not yet proven a sustainably premium margin through the cycle.

Coating Solutions sits downstream of Arkema's own acrylic monomer production, which reports inside Primary Materials under the 2026 segmentation. The segment itself runs two business lines, coating resins and coating additives, spanning waterborne resins for decorative paints, Sartomer photocure technologies and specialty additives. Acrylics are an input cost here rather than a source of spread. Q2 sales increased 4.9% and EBITDA surged 52.9%, producing an 18.5% margin. Volumes were up 5.7%, and pricing actions did much of the rest; a 4.2% negative scope effect from divesting small plastic-additives businesses also improved mix, and Arkema attributes the margin jump to that portfolio refocusing plus pricing agility. Extrapolating the 52.9% EBITDA growth into a structural run rate would be aggressive.

Primary Materials is a reminder of the old Arkema. Q2 pricing rose 16.0% while volumes dropped 9.7%. Acrylic monomer prices climbed after the Middle East shock; European monomer demand and legacy refrigerant volumes stayed weak. Favorable spreads lifted EBITDA 30.3% to EUR 57.7 million. That is profitable cyclicality rather than a moat, and if raw-material and monomer markets normalize, the pricing component can reverse quickly.

The Q2 release does not give a sufficiently granular percentage table for every end market, so I do not manufacture one. Arkema's own market taxonomy spans construction, packaging, automotive and transportation, electronics, energy, consumer goods, healthcare, sports and industrial applications. The earnings call material makes the transmission chain clearer: construction affects adhesives and coatings; automotive and industrial production affect adhesives and technical polymers; electronics and batteries pull PA11, PVDF and polyimide materials; refinery and fertilizer activity affects Performance Additives; and energy/raw-material markets influence input costs and acrylic spreads.

That leaves Arkema exposed to several overlapping cycles rather than one chemical cycle. Macroeconomic and construction activity moves volumes, and an inventory cycle magnifies that movement as distributors and manufacturers destock or restock. Acrylic, sulfur and energy spreads follow a commodity/feedstock cycle of their own. Automotive and electronics carry their own production cycles. Battery materials add a capacity-and-technology cycle in which end demand can grow rapidly while material prices fall because supply grows faster.

The quarterly numbers make operating leverage visible. Advanced Materials lost 13.2% of EBITDA on a 3.1% sales decline; Coating Solutions grew EBITDA 52.9% on 4.9% sales growth. Utilization, mix, raw-material spreads and price realization account for the difference. Arkema's factories carry meaningful fixed labor, maintenance and depreciation, and when volumes leave a high-value line those costs do not disappear. The reverse also holds: incremental volumes through an already built line can carry attractive margins.

The same cost base explains why the EUR 90 million savings objective matters. Raw materials, freight and some energy vary with production; the staffing, safety, environmental compliance, maintenance and utility infrastructure of a chemical site are fixed. Research and development is another recurring requirement rather than discretionary “growth” spending: FY2025 R&D expense of EUR 284 million equaled 3.1% of the EUR 9.068 billion of sales and rose 4% at constant currencies in a year of fixed-cost cuts. A company built around specialty differentiation has to keep that spending even when demand falls.

The first real moat is technical/application qualification in high-performance niches. Customers design PA11, PVDF, polyimide films and certain specialty adhesives into systems that carry performance, safety and qualification requirements. Changing suppliers can require reformulation, testing and production-line requalification. Those frictions produce switching costs that a generic chemical producer lacks: strongest in aerospace, electronics, batteries and industrial assembly, and weaker in commoditized intermediates.

The second moat is accumulated process chemistry. Arkema's strategy identifies polymerization and formulation as core technical capabilities, and the investment record shows management willing to replicate those processes at industrial scale. Quality consistency, resin properties, qualification and application support all matter, which is why new PA11 and PVDF capacity is not simply a warehouse full of undifferentiated material. The moat should nevertheless be graded by product. Battery-grade PVDF faces intense capacity additions, particularly in Asia, so chemistry know-how does not guarantee scarcity rents.

The third is customer proximity in adhesives and coatings. Formulators frequently win business by solving production problems rather than by being the cheapest molecule. Bostik's presence across construction, packaging and industrial assembly gives it local application laboratories, commercial relationships and a broad product catalogue. The cleaner Q2 Adhesives pricing outcome shows the quality of this moat: positive pricing and mix persisted despite weak construction and packaging volumes.

The fourth is manufacturing footprint and scale. Arkema has built industrial platforms in North America, Europe and Asia, including Beaumont, Calvert City, Changshu, Kerteh and Singapore. That footprint means a multinational customer can source qualified material across regions and Arkema can locate incremental capacity near demand. The company says its geographic sales mix is now roughly balanced across the three major regions, a large improvement from its European-heavy starting position.

The weaker “moat” is the specialty label itself. Q2 provides a clean reality check. Group volumes were down 1.8%, and a large portion of the 5.1% positive price effect reflected input inflation, scarcity or chain-specific spreads. Primary Materials pricing was up 16% during a geopolitical shock, and Performance Additives was actively raising prices to offset sulfur inflation. Those are necessary commercial responses, but pass-through is different from durable pricing power. A true moat shows up when price/mix remains favorable after feedstock pressure fades and customers have alternatives.

Management's capital-allocation score is similarly mixed rather than binary. Le Hénaff's best evidence is the 36%-to-85% specialty shift over twenty years: the acquisitions created platforms that materially changed what Arkema sells, and disposals removed obvious commodity baggage. That is a more substantive record than a strategy presentation. The counterweight is the present balance-sheet burden. At 2.9 times net debt plus hybrids to LTM EBITDA, investors now need to see returns, integration and deleveraging rather than another transformation-size transaction.

The 2025 growth-project result deserves attention for the same reason. On time and budget, the projects delivered roughly EUR 60 million of incremental EBITDA compared with 2024, yet contributed less than management originally hoped. That suggests the main risk was demand/ramp utilization rather than engineering execution. A factory delivered on budget does not create shareholder value until customers buy enough high-margin material through it.

The current project slate is tangible. Rilsan Clear capacity in Singapore began ramping in early 2026 and is intended to roughly triple global capacity for that product family. Calvert City started a roughly 15% PVDF capacity expansion in Q2, while another roughly 20% increase at Changshu is expected in 2028. Management estimates the large projects contributed about EUR 25 million of incremental EBITDA in H1 2026 and should contribute roughly EUR 50 million for the full year.

Regulation cuts both ways. Policies favoring lightweight vehicles, energy efficiency, electrification and recyclable packaging can increase demand for advanced adhesives and polymers. Fluorinated chemistries also create a long-tail liability. In France, PFAS contamination around the Pierre-Bénite chemical valley has led to litigation involving Arkema and Daikin, and Le Monde reported that 192 plaintiffs sought nearly EUR 36.5 million in damages in proceedings opened in 2026. The much larger regional cleanup-cost figures discussed publicly are not equivalent to a booked Arkema liability and should not be treated as one.

Arkema itself recorded EUR 46 million of Q2 exceptional expense, mainly related to the Jarrie and Pierre-Bénite reorganizations, ongoing legal proceedings and smaller plastic-additive disposals, but it did not isolate a PFAS liability of that amount. The correct risk framing is an uncertain legal and remediation tail, not a known EUR 2 billion Arkema obligation or similar headline extrapolation.

Geopolitics is already more immediate than the long-tail regulation debate. Brent crude had moved above USD 100 by September 9, 2026, amid escalating Middle East tensions, increasing European inflation and rate concerns. For Arkema that can mean higher sulfur, energy and petrochemical feedstocks, customer outages, shipping disruption and temporary selling-price opportunities. Q2 showed both sides at once: higher input costs hurt Performance Additives while acrylic pricing helped Primary Materials.

That combination defines Arkema's cycle position in September 2026. Industrial volumes are not yet healthy enough to call a full recovery. Cost actions and price realization have improved earnings, new capacity is ramping, and certain electronics/battery/three-dimensional-printing applications are growing strongly. Set against that, European chemicals remain under structural pressure, construction demand is subdued and Middle East cost volatility has increased. The company appears nearer the trough than the 2022 peak, but the evidence for a broad volume upcycle remains incomplete.

Horizontal competitor analysis

Arkema has enough overlap with several public companies that Scenario C, an ample-peer landscape, is the appropriate framework. No single company is a clean comparable, because Arkema combines formulated adhesives, advanced polymers, specialty additives, acrylic coatings technology and the cyclical Primary Materials activities. The most informative set uses different peers to illuminate different pieces: Sika for adhesives/formulation quality, Syensqo for high-performance specialty materials, Victrex for high-performance polymer economics, Saint-Gobain for downstream construction exposure, and Evonik for diversified European specialty-chemical cyclicality.

Sika is the most important quality benchmark because it shows what a formulation-heavy business can become when customer intimacy, specification selling and global distribution dominate the economics. Its construction chemicals, sealants and adhesives overlap Bostik, but its portfolio is materially less exposed to upstream chemical spreads. Even after 2025 reported sales fell 4.8%, Sika generated roughly an 18.4% EBITDA margin and targeted 19.5–20.0% for 2026. That is a useful yardstick against Arkema's 13.8% group margin in 2025 and 16.1% in the favorable Q2 2026 quarter.

Customers pick Sika when the chemistry is embedded in a complete construction or industrial process: concrete additives, waterproofing, sealing, bonding and reinforcement can be specified together and supported locally. Bostik increasingly has that character, but it represents about 30% of Arkema sales rather than almost the entire group. The horizontal conclusion is straightforward. Bostik gives Arkema a premium formulation engine; it has not yet transformed the economics of the remaining 70% enough to justify valuing all Arkema as Sika.

Syensqo is the more useful comparison for Advanced Materials. Its portfolio inherited a concentration of Solvay's specialty polymers, composites and high-value materials serving aerospace, automotive, electronics and other demanding applications. Customers choose these materials for qualification, performance and engineering support, not simply price per kilogram. Arkema competes from a somewhat broader base that includes bio-based PA11, PVDF, polyimide films and performance additives. Its advantage is diversification across adhesives and coatings; its disadvantage is a portfolio that carries more visible commodity and construction-cycle leakage.

Victrex supplies the purest version of the high-performance-polymer thesis. PEEK and related polymers can earn attractive economics because the material goes into high-temperature, chemically demanding or safety-sensitive applications and can remain specified for years. The business is much narrower than Arkema, so Victrex is a technology-quality benchmark rather than a valuation twin. It illustrates the upside if Arkema's specialty polymer franchises command persistent qualification rents, and the concentration risk when a handful of end markets slow.

Saint-Gobain belongs in the comparison for a different reason: it sits much further downstream, in construction materials and building systems. The overlap with Arkema is demand, not molecular technology. When new construction, renovation and industrial building activity weaken, Saint-Gobain and Arkema's construction adhesives/coatings feel the same macro impulse at different points in the value chain. That makes Saint-Gobain useful for separating “Arkema-specific execution” from “the building cycle is weak.”

Evonik is the closest broad European specialty-chemical sanity check. It owns additives and specialty-material businesses, faces a high-cost European industrial base, and has pursued portfolio simplification and cost restructuring. Its 2026 outlook became more constructive as pricing, volumes and cost actions improved; public reporting in 2026 put adjusted-EBITDA guidance at EUR 2.0–2.2 billion. What matters for Arkema is the demonstration, not Evonik's absolute size: European specialty chemicals can experience margin recovery before the macro environment looks healthy if companies reduce costs and stabilize price/mix.

A narrow numerical comparison explains why Arkema's valuation discount is understandable. The figures below deliberately avoid mixing market-cap data reported in different currencies and dates, and sales growth appears on two bases because the 2025 currency effect was negative 2.9 percentage points for Arkema and negative 5.4 percentage points for Sika, so a single mixed row would misrank them.

† Arkema's 16.1% is a quarterly result, not full-year guidance. Arkema uses its own non-IFRS EBITDA definition; Sika and Evonik measures are company-defined and not perfectly accounting-identical.

The numbers show the underlying business-quality hierarchy more clearly than a raw product list. Arkema's group margin has room to recover from the depressed 2025 base, while Sika's margin demonstrates that a formulation-heavy model can sustain structurally higher profitability. Arkema would deserve a smaller discount if Adhesive Solutions raises its margin, Advanced Materials restores growth without sacrificing price, and Primary Materials becomes economically less important.

Breadth across three different specialty technologies is Arkema's relative strength against the peer set. A customer designing a lighter, bonded, coated component can potentially encounter Arkema in the polymer, adhesive and coating stack. That breadth spreads end-market risk and gives management multiple reinvestment options. The weakness is the reverse side of the same breadth: the company is harder to understand, carries more upstream assets and gives investors fewer pure-play economics.

Against Sika, Arkema has deeper polymer chemistry and more exposure to electronics, batteries and advanced materials; Sika has the cleaner formulation model and stronger group margin profile. Set beside Syensqo and Victrex, Arkema is more diversified and has a larger adhesives platform, while those companies offer cleaner exposure to premium advanced materials. Arkema is smaller than Saint-Gobain and more technologically concentrated but has more direct feedstock risk. Next to Evonik, Arkema's portfolio transformation appears further toward three named growth platforms, while both retain exposure to the competitiveness of European chemical production.

The market's valuation hierarchy should therefore differ. Handing Arkema Sika's multiple in a blanket peer-multiple exercise would capitalize earnings as though Primary Materials, cyclical acrylics and weak-volume Performance Additives did not exist. A commodity-chemical multiple would make the opposite error and ignore Bostik, PA11, PVDF, polyimide films and specialty coatings. Arkema belongs between those endpoints.

The ecological niche is best described as a diversified specialty-materials challenger with pockets of genuine technical leadership. It is too broad to be a pure niche player and too small to dictate industry pricing across its markets. Its strongest profit pools are applications where material cost is low relative to the value of failure avoidance, weight reduction, manufacturing speed or durability. Its weakest pools are those where selling price follows feedstock spreads.

Technological substitution would affect Arkema unevenly. Successful lightweighting, electrification and advanced assembly can strengthen adhesives and performance polymers. Battery-material overcapacity could weaken PVDF economics even while battery volumes rise, and tighter PFAS regulation could increase compliance cost or force substitution in some fluorinated materials. A construction downturn hurts Bostik but may simultaneously give a disciplined acquirer opportunities. The portfolio is a bundle of different competitive positions, not one moat.

For valuation purposes I do not use an exact current peer-multiple table, because I could not verify clean EV/EBITDA estimates for all five peers from a single September 9–10 timestamp and consistent accounting definitions. A mixture of vendor dates and EBITDA definitions presented to two decimal places would look precise while being analytically weaker. The horizontal conclusion that holds up is relative rather than pseudo-exact: Arkema deserves a meaningful discount to the formulation-quality leader Sika, while its improved specialty mix warrants better economics than a traditional European commodity-chemical basket.

Current fundamentals and bull-bear divergence

The latest six months contain a distinct turn. H1 2026 sales were EUR 4.610 billion against EUR 4.776 billion in H1 2025, a reported decline of 3.5%. H1 EBITDA fell 2.7% to EUR 673.5 million, yet the margin edged up to 14.6% from 14.5%. So the first quarter was much weaker than the second. Subtract Q2 from the H1 figures and Q1 2026 works out at approximately EUR 2.182 billion of sales and EUR 282.6 million of EBITDA, against EUR 2.381 billion and EUR 328.6 million a year earlier: reported sales down about 8.4%, EBITDA down about 14.0%, and an EBITDA margin near 13.0%. These Q1 figures are arithmetic derived from Arkema's H1/Q2 disclosure rather than separately reported estimates.

Q2 moved the other way. Reported sales rose 1.3%, organic sales rose exactly 3.2% on Arkema's definition, and EBITDA gained 7.4%. The margin jumped to 16.1%. That sequential change is the strongest current bull evidence, because it shows cost measures, pricing and mix can materially change earnings even before volumes broadly recover.

The following bridge should prevent the two growth concepts from being confused.

Arkema defines organic development by excluding scope and currency effects. It does not treat capacity additions as scope changes. The individually rounded price and volume numbers add to 3.3%, but the company reports 3.2% organic growth from its unrounded calculation. Likewise, rounded bridge components do not have to algebraically reproduce reported growth to one decimal point.

That distinction is unusually important this quarter. A secondary summary quoting 3.3% is effectively adding rounded price and volume numbers. Arkema's official result is 3.2%. Conversely, the 1.3% reported increase includes currency and perimeter. Neither figure should be substituted for the other.

The EBITDA measure needs equal care. Arkema states explicitly that EBITDA is an alternative performance measure, not an IFRS-defined measure. It starts from IFRS operating income and adds recurring depreciation and amortization, depreciation and amortization resulting from purchase-price allocation, and “other income and expenses.” The company uses the measure to assess operating profitability before working-capital, capital-investment, financing and tax effects.

The Q2 reconciliation is:

Components differ from the reported total by EUR 0.1 million because of rounding. Every EV/EBITDA multiple in this report uses this Arkema-defined EBITDA, not an independently standardized EBITDA.

Adjusted EBIT was EUR 219.5 million in Q2 against EUR 197.8 million a year earlier, while IFRS operating income came in at EUR 141.4 million and attributable net income at EUR 65.7 million. The gap illustrates why headline P/E and adjusted P/E can tell very different stories for an acquisitive specialty-materials company: purchase-price amortization and exceptional restructuring/legal items sit between operating economics and statutory earnings.

Coating Solutions was the best-performing business. Volume growth of 5.7% and swift pricing actions that outran input-cost inflation together lifted EBITDA by EUR 27.1 million year on year. The improvement is broad enough to matter, but the prior-year margin of 12.7% was depressed. The benchmark that counts is whether the segment can sustain a mid-to-high-teens margin once acrylic input costs and the pricing response normalize.

Adhesives offers a more modest but arguably higher-quality improvement. Sales rose 2.7% reported and 3.8% organically, EBITDA rose 7.3%, and margin expanded 60 basis points to 15.1%. Durable-goods markets, aerospace, consumer electronics and industrial assembly helped; construction and packaging volumes stayed weak. If those lagging markets recover, that would create operating leverage without requiring another round of aggressive pricing.

Advanced Materials is the main counterexample to a clean recovery narrative. Reported sales fell 3.1%, with a 2.1% positive price effect overwhelmed by a 3.6% volume decline and a 1.6% currency headwind. EBITDA fell EUR 24.7 million and margin lost 220 basis points. Arkema still reported growth in batteries, electronics and three-dimensional printing, but Performance Additives was weaker on Middle East-related refinery/fertilizer demand and input costs.

Primary Materials made more money, for reasons investors should treat cautiously. Higher acrylic-monomer prices helped EBITDA, but volume weakness remained severe, and Arkema said Asian acrylic spreads had already fallen back to low levels from May. Legacy refrigerants are also a structurally declining activity rather than an earnings-growth engine. Q2's EUR 57.7 million EBITDA should not be annualized automatically.

The growth-project evidence is more encouraging. Rilsan Clear, U.S. PVDF and other major investments supplied about EUR 25 million of incremental H1 EBITDA versus the previous year, which puts management halfway to its roughly EUR 50 million full-year goal. Because 2025's project contribution underdelivered initial expectations even though the facilities were physically ready, utilization and customer take-up are the variables that matter now.

The expense program matters just as much. Management targeted approximately EUR 90 million in 2026 savings versus 2025 and cut headcount by about 365 positions during H1. If those savings persist, they represent roughly 7% of 2025 EBITDA, before considering wage inflation and normal reinvestment. The program can cushion a soft volume environment, but investors should treat only part of gross savings as permanent incremental EBITDA because inflation absorbs some of it.

Consensus before the Q2 print gives a useful expectation anchor. Analysts in Arkema's published snapshot expected Q2 EBITDA of about EUR 362 million and FY2026 EBITDA around EUR 1.259 billion. Actual Q2 EBITDA was EUR 390.9 million. If the full-year consensus did not rise, the implication would be that analysts expect some of Q2's margin strength to normalize in H2. A current, independently verified post-Q2 analyst-consensus series was not available in the source set, so I do not claim that aggregate estimates have since risen by a specific amount.

Through September 10, the company had not issued a later trading update changing guidance. The next scheduled financial event is Q3 2026 results on November 5, 2026. The market will have to wait another quarter to establish whether Q2's improvement is repeatable.

The market is trading a margin-led recovery before it has evidence of a volume-led recovery.

The bull case rests first on the arithmetic of the trough. If 2025's EUR 1.251 billion EBITDA was depressed by weak European/U.S. demand, start-up dilution and underutilized growth projects, even modest volume normalization can recover fixed costs quickly. Q2's 16.1% margin is evidence that the transformed portfolio can earn substantially more than the 13.8% FY2025 margin when mix and spreads cooperate.

Second, the capex is beginning to earn. The 2026 project target adds roughly EUR 50 million of EBITDA versus 2025 with no acquisition needed, and new PA11/PVDF/polyimide capacity addresses end markets that were still growing around 15% in pockets such as batteries, electronics and three-dimensional printing during Q2. A recovery in industrial volumes would sit on top of that project contribution.

Third, valuation does not require premium-specialty perfection. At roughly 6.4 times FY2026 consensus Arkema-defined EBITDA and about 12.5 times consensus adjusted earnings, the market is charging investors considerably less than it would for a stable high-teens-margin compounder. If group EBITDA returns toward EUR 1.4–1.5 billion while debt falls, equity value can rise even without a heroic multiple.

The bear case begins with volumes. Group volume was still down 1.8% in Q2, despite the much better EBITDA result. Advanced Materials volume declined 3.6%, Primary Materials 9.7%, and construction/packaging remained weak for Adhesives. A company can protect margins with price and cost only for so long if its plants stay underloaded.

Second, the quality of Q2 pricing is debatable. Primary Materials' 16% price increase was tied to a disrupted acrylic market; Performance Additives was repricing against sulfur inflation; and Middle East tensions remained severe in September. If feedstock conditions reverse, selling prices can decline. The pricing bridge therefore cannot be treated as a permanent 5% organic-growth engine.

Third, debt turns an ordinary cyclical miss into an equity problem. At 2.9 times net debt plus hybrids to LTM EBITDA, another EUR 200–300 million EBITDA downturn would raise leverage significantly before management has time to cut fixed costs. It would constrain acquisition capacity, make the dividend less comfortable and justify a lower valuation multiple at the same time earnings are falling.

Fourth, the transformed portfolio carries technology-transition risk of its own. PVDF capacity is growing industry-wide, particularly around batteries, and specialty-chemical growth markets do not guarantee attractive producer returns when competitors add too much supply. Arkema's new capacity increases earnings only if utilization, mix and price are adequate. The relevant warning is 2025, when project contribution came in below expectation despite on-time delivery.

Fifth, PFAS creates asymmetric legal and regulatory exposure. Current claims are not large enough to define the investment thesis, and the publicly discussed regional remediation bill cannot be assigned wholesale to Arkema. The tail matters because a future change in regulation, liability allocation or remediation requirements could generate cash costs that current adjusted EBITDA does not contain.

Valuation, risk, catalysts, tracking, and cross-synthesis

The valuation has to start with a cash-flow warning. Arkema's adjusted EBITDA serves operating analysis well, but it sits a long way from cash available to equity holders. It adds back recurring depreciation, acquisition-related amortization and exceptional costs. The real company must continually maintain chemical plants, pay interest and taxes, absorb working capital and fund environmental obligations. Any valuation that simply multiplies EBITDA without adjusting debt and reinvestment will overstate equity economics.

Cash-flow passthrough. Arkema consistently publishes “recurring cash flow,” an alternative measure that tells an owner more than EBITDA does, because it reflects recurring investment spending. FY2025 recurring cash flow was EUR 464 million; H1 2026 ran negative at EUR 17 million, better than the negative EUR 26.9 million of H1 2025, while Q2's own EUR 78.3 million was 29.3% below the EUR 110.7 million of Q2 2025. The retrieved primary-source set holds no clean, restated five-year table of IFRS cash flow from operations and IFRS net income on an identical perimeter. So I do not manufacture the exact five-year CFO/net-income ratio that a textbook screen demands. Call it a disclosed research limitation.

Normalized owner cash makes the better test. Arkema does not break out maintenance and growth capex. Guidance caps FY2026 total capex at EUR 600 million, while H1 recurring depreciation and amortization annualizes to roughly EUR 670 million. Given the identified growth projects still inside the capex program, I assume EUR 350–450 million of annual maintenance capital and roughly EUR 150–250 million of growth/expansion spending. Those are research assumptions, not company disclosures, and the exact split is one of the most important unknowns in the valuation.

Take the Q2-era FY2026 EBITDA consensus of EUR 1.259 billion. Subtract approximately EUR 350–450 million maintenance capex, normalized cash interest around EUR 120–150 million and cash tax of roughly EUR 150–200 million, and the indicative owner-earnings range lands around EUR 460–640 million before unusual working-capital movements and exceptional environmental/restructuring cash. At the EUR 4.42 billion market cap, that is an owner-earnings yield of roughly 10.4–14.5%, or about 6.9–9.6 times normalized owner earnings. The assumptions matter more than the apparent precision of the range, maintenance capex most of all.

The same stock trades at approximately 12.5 times Arkema's Q2-era consensus adjusted EPS of EUR 4.65. The owner-cash midpoint sits roughly 40% above the implied adjusted net-income base, a greater-than-30% difference in earnings-yield terms. The direction of that gap rests on assumptions Arkema does not explicitly disclose, so the scenario work defaults to owner cash and EV/EBITDA rather than headline P/E.

On the conservative convention used here, current enterprise value is approximately EUR 8.02 billion: EUR 4.42 billion equity value plus EUR 3.605 billion of net debt and hybrids. Against FY2026 consensus EBITDA of EUR 1.259 billion, that is about 6.37 times company-defined EBITDA. Vendor enterprise values that treat hybrid bonds as equity may produce a lower multiple. I include hybrids on purpose: Arkema itself includes them in the 2.9-times leverage measure, and the cash claims matter when stress-testing ordinary equity.

Historical-percentile claims deserve caution. The primary-source set contains no continuous ten-year, consistently defined forward-EV/EBITDA series, so I will not label the current multiple “20th percentile” or anything similar. What can be established is narrower: today's multiple prices Arkema as a discounted cyclical specialty-materials company rather than a premium formulation compounder. Its 6.4-times forward EBITDA multiple and 6.2% indicated dividend yield leave far more cyclical skepticism in the price than the 2021–2022 earnings peak narrative did.

Peer valuation should be read in that context. Sika's higher structural margin and lower upstream commodity exposure justify a premium. Victrex and Syensqo can deserve technology premiums in high-performance materials, though their end-market risks are narrower. Evonik is the reminder that low European specialty-chemical multiples can coexist with real cost-improvement potential. Arkema should not be called cheap merely because Sika is expensive; its absolute cash return and balance sheet have to work without a peer rerating.

The absolute scenarios below run on a three-year normalization frame. I keep revenue assumptions deliberately secondary to EBITDA, because portfolio changes, price pass-through and scope can turn revenue growth into a poor proxy for economic improvement. All multiples are on Arkema-defined EBITDA. Net debt includes hybrids.

† Total-return calculation assumes the share reaches the midpoint of each valuation range after three years and receives three unchanged EUR 3.60 dividends. It ignores tax and dividend reinvestment. It is scenario analysis, not a forecast. Current price as of 2026-09-09.

The conservative case assumes today's volume weakness turns persistent rather than temporary. Cost savings and new projects arrive, but price normalization and underutilization consume the gains, so EBITDA stays around or below the 2025 level. Net debt declines only modestly. A 5.5–6.0 times multiple then produces equity value in the high EUR 30s to low EUR 50s.

In the base case Arkema proves the portfolio is better than the 2025 earnings trough without recreating 2022 scarcity economics. Adhesive volumes recover moderately, Coatings holds a normalized mid-teens-plus margin, Advanced Materials picks up project contributions and better utilization, and recurring cash generation pays down debt. EUR 1.30–1.40 billion EBITDA remains well below the 2022 peak, so the scenario never has to assume a boom.

The optimistic case requires much more: a broad industrial recovery, successful utilization of new PA11/PVDF/polyimide capacity, durable Adhesive margin expansion, no severe PFAS cash cost and meaningful deleveraging. Behind the 7.2–7.7 times multiple sits an assumption that the market concludes Arkema's portfolio quality has structurally improved. EUR 104–124 per share is therefore a proof-of-quality scenario, not a simple cyclical bounce.

Catalysts differ across the cases. The near-term positive that matters most is Q3 showing that Q2's margin improvement survives without extraordinary Primary Materials pricing. A return to positive group volume growth would be worth more than another quarter driven primarily by price. Hitting the EUR 50 million project contribution and EUR 90 million savings targets would establish that management's self-help is working. Net debt moving decisively below 2.7 times EBITDA would improve equity optionality.

The negative catalysts are just as observable. A guidance cut on November 5 would undermine the idea that Q2 was a turn. If Advanced Materials margin stays below roughly 18% despite the project ramp-up, that would question returns on recent capital. A renewed working-capital build, or FY recurring cash flow materially below 2025, would make deleveraging harder. Persistent Middle East disruption could maintain sulfur/feedstock inflation while depressing refinery and fertilizer demand. A material new PFAS provision would change the cash-flow bridge directly.

That concentrates the expectation gap in three variables: volumes, the durability of price/mix, and cash conversion. The market already knows Arkema has spent the capex, and it knows management expects EUR 50 million of project contribution. The surprise will come from whether customers fill that capacity, whether pricing survives falling feedstock costs, and whether EBITDA becomes cash quickly enough to reduce the EUR 3.6 billion debt-plus-hybrid load.

The next report, on November 5, 2026, should be judged first on organic volume rather than reported sales. Currency and scope can obscure the operating signal, while another inflation-driven price increase could flatter organic sales. Second comes Advanced Materials margin, which carries both the company's highest-quality growth narrative and the current Performance Additives weakness. Third, leverage and cash flow. Those three numbers together will determine whether Q2 was a business turn or just a favorable spread quarter.

The thresholds in the table below are analytical, not management guidance except where explicitly identified.

The project, capex and earnings-date rows rest on company guidance from Arkema's Q2 materials; all other cutoffs are this report's monitoring thresholds.

Prolonged weak industrial demand carries the highest near-term probability. I rate probability medium-to-high and impact high. The observable indicator is organic volume remaining below zero, particularly in Advanced Materials and Adhesives. Transmission is direct: lower utilization depresses contribution margin, the fixed chemical-plant cost base remains, project returns are delayed, leverage stays high and investors cut the EV/EBITDA multiple. Q1's 14% EBITDA decline on an 8.4% sales fall, and Q2 Advanced Materials' 13.2% EBITDA decline on a 3.1% sales fall, show the operating leverage at work.

Second: balance-sheet duration. Current evidence puts the probability of financial distress low, but the probability that leverage constrains shareholder returns is medium, and impact can be high in a downturn. The indicator to watch is debt plus hybrids/LTM EBITDA above 3 times after seasonal working capital normalizes. If EBITDA drops while debt stays around EUR 3.5 billion, a lower multiple applies to a smaller enterprise-earnings base and the debt claim remains fixed. Equity absorbs both effects.

Third, price normalization. Probability medium, impact medium-to-high, because the Q2 recovery leans materially on price/spread effects. The alert is group price contribution turning negative before volumes recover, or Primary/Coatings EBITDA falling despite stable sales. From there the path runs through lower revenue per ton, margin compression, and a market conclusion that Q2's 16.1% group margin overstated the normalized level.

Fourth, project-return disappointment: probability medium, impact medium. Management has already shown it can deliver physical projects to schedule and budget while EBITDA contribution trails expectation. Watch the EUR 50 million 2026 incremental-project target, utilization of Singapore PA11/Rilsan Clear and Calvert City PVDF, and Advanced Materials margin. If global capacity additions absorb the demand growth, project EBITDA arrives slowly while depreciation, interest and invested capital are already present.

Fifth, PFAS and environmental liability. Some continuing litigation and compliance cost is a high-probability outcome; a balance-sheet-transforming liability is currently low-to-medium probability and impossible to quantify responsibly. In the tail, impact is high. The observable indicators are new provisions, court rulings, remediation agreements and product restrictions. The route to value destruction runs through cash remediation, additional capex, potential customer substitution and a higher risk discount applied to fluorinated-product earnings. The existing French plaintiffs' claim is evidence of the pathway, not evidence of the eventual loss amount.

Sixth, geopolitics and feedstocks: probability medium-to-high in the immediate environment, impact medium. The September oil shock and the Q2 sulfur issue show it is already active. Arkema can often reprice, but with a lag. Raw materials move immediately, contracts reprice later, customers reduce production, and working capital may rise as inventory becomes more expensive. The risk becomes structural only if Middle East instability changes regional energy and industrial economics for several years.

Margin-of-safety recheck. The conservative scenario puts equity value at roughly EUR 37–53 per share, midpoint near EUR 45. The current EUR 58.05 price sits above even the conservative range's upper end. Under the framework specified in the assignment, the current price therefore provides zero margin of safety relative to the conservative case.

The base case's most fragile assumption is the valuation multiple. EUR 1.30–1.40 billion EBITDA is achievable without recreating 2022, while a 6.3–6.8-times multiple still depends on investors accepting Arkema as a better-quality specialty company. Cut the midpoint multiple to 70% of the base assumption, from about 6.55 times to 4.59 times, hold EUR 1.35 billion EBITDA and EUR 3.2 billion debt plus hybrids, and equity value comes out at only about EUR 39 per share. That is why modest-looking multiple compression matters so much when debt is large relative to market capitalisation.

If earnings and the EUR 3.60 dividend were completely flat for three years and the share still traded at EUR 58.05 at the end, three cash dividends would produce an annualized nominal total return of roughly 5.9% before tax. The primary source set gives me no French ten-year OAT quote timestamped well enough to force the requested bond-yield comparison to a false decimal. So this sub-test does not drive the conclusion. The conservative-value premium already does.

The margin-of-safety sufficiency verdict is none. That does not make the base case unattractive. It means the current price relies on at least some earnings normalization and does not compensate an investor for the conservative scenario by the requested 20% buffer.

The decision bands come mechanically off the scenarios. A conservative midpoint of about EUR 45 sets a strict 20%-plus margin-of-safety purchase ceiling around EUR 36, so the ideal-buy zone is EUR 32–36. The base midpoint is about EUR 74, which makes a ±15% hold zone approximately EUR 64–85. The optimistic midpoint is about EUR 114; 10% above that is roughly EUR 125, so EUR 126 and above marks clear overvaluation under these assumptions.

At EUR 58.05 those bands produce an unusual but analytically coherent result: the shares are cheaper than the base-case hold zone, yet not cheap enough for the conservative-case buy discipline. The stock sits in the gap between “enough upside if normalization occurs” and “enough downside protection if normalization fails.”

The vertical record shows one capability genuinely proven: management can reshape a large industrial portfolio over decades. Moving Specialty Materials from 36% to roughly 85% of revenue, integrating Bostik, exiting large legacy businesses and building global capacity in specialty polymers took persistence across several cycles. That capability is more credible than any short-term margin target.

Past success nevertheless came from a mixture of management skill and era tailwinds. The portfolio shift was management-made. The 2021–2022 earnings peak was partly cycle-made. Scarcity pricing, reopening and strong industrial demand amplified the returns from the new portfolio. The fall to EUR 1.251 billion EBITDA in 2025 showed that Arkema had improved its business but had not eliminated cyclicality.

Horizontally, Arkema's biggest advantage is that it owns several difficult-to-replicate specialty-material platforms while remaining broad enough to serve many industries. Its weakness is that investors have to pay for and finance a large manufacturing base to access them. Sika can be understood principally as a formulation/customer-intimacy machine, Victrex principally as a high-performance-polymer niche. Arkema is a portfolio of both types plus the cyclical Primary Materials activities, and that complexity deserves some conglomerate/cycle discount.

The market may currently be underestimating the earnings sensitivity to even modest volume stabilization. Q2 showed that a 16% group EBITDA margin is possible before a broad volume recovery. With new projects contributing and costs coming out, a move from negative volumes to zero or low-single-digit growth could lift EBITDA faster than revenue. No other part of the thesis carries upside asymmetry this large.

The market may simultaneously be overestimating the permanence of Q2 pricing. A 5.1% price contribution alongside -1.8% volumes looks powerful in isolation. Break it apart and it looks thinner: acute acrylic pricing, sulfur pass-through, mix and manufacturing-agreement effects all contribute. Positive volume with a stable margin, after those price shocks normalize, would be the better evidence of sustained earnings quality.

At one year, the critical variables are organic volume, Advanced Materials margin, project EBITDA and net leverage. Stretch to three years and they become returns on the completed growth-capex program, Adhesive margin progression, and whether debt can fall toward a level that gives management genuine capital-allocation freedom. The five-year question is more structural: whether Arkema can deliver through-cycle group economics sufficiently close to premium-specialty peers to make the twenty-year portfolio transformation economically complete.

A better investment setup would therefore require one of two things. Price is the first: a move toward EUR 32–36 without deterioration in the underlying specialty franchises would provide the conservative-case margin of safety that is absent today. Proof is the second. Persistent positive volumes, Advanced Materials margin around or above the high teens, Adhesives moving sustainably above 15%, annual recurring cash generation comfortably above EUR 400 million and leverage below roughly 2.5–2.7 times would justify paying a higher price, because the probability distribution itself would have improved.

The opposite pattern should overturn the judgment negatively: new capacity remains underutilized, Advanced Materials margin settles below roughly 17.5%, net leverage remains above 3 times after the investment cycle, or PFAS obligations become large enough to alter free cash flow. In that world the transformation would have improved product mix without producing an adequate return on capital.

The core bull reasons stay short because the evidence is already developed above:

• Specialty Materials now represent about 85% of sales versus 36% in 2006, leaving the underlying portfolio materially less commodity-like than Arkema's historical valuation label implies.
• Q2 2026 EBITDA rose 7.4% and margin reached 16.1% even though group volume declined 1.8%, evidence of sharp earnings sensitivity if volumes stabilize.
• Major growth projects added about EUR 25 million of incremental H1 EBITDA and are targeted to contribute about EUR 50 million for 2026, self-help that does not depend on a full macro recovery.
• At EUR 58.05 the equity trades near 6.4 times Q2-era FY2026 consensus company-defined EBITDA, so the current valuation does not require Sika-like premium margins.

The core bear reasons are just as concrete:

• Q2 group volume remained down 1.8%, with Advanced Materials volume down 3.6% and Primary Materials down 9.7%, so the earnings turn has not yet become a demand turn.
• The 5.1% group price contribution contains substantial raw-material, scarcity and mix effects, so it cannot safely be capitalized as permanent pricing power.
• Net debt plus hybrids of EUR 3.605 billion and leverage of 2.9 times LTM EBITDA amplify both earnings downside and multiple compression.
• Recent growth projects landed physically but contributed less EBITDA than initially expected in 2025, proof that on-budget capacity does not guarantee an adequate financial return.
• PFAS litigation around Pierre-Bénite creates an unquantified cash-cost tail that adjusted EBITDA cannot capture.

A concrete three-year pre-mortem starts with advanced-material overcapacity. Suppose that through 2027–2028 Chinese PVDF additions and competing high-performance suppliers, Syensqo and Asian producers among them, keep battery-grade material pricing under pressure while European industrial demand remains weak. Arkema's new PVDF and related advanced-material capacity then runs materially below plan, Advanced Materials EBITDA margin falls from 18.7% toward 14–15%, and group EBITDA drops toward EUR 1.0 billion. If debt plus hybrids remain around EUR 3.4–3.6 billion and the market applies a 5-times EBITDA multiple, equity value could fall toward roughly EUR 20–25 per share. That would represent around a 60% permanent-capital loss from EUR 58.05. It is a stress scenario, not a forecast, and the mechanism is specific: excess capacity lowers price and utilization at the same time fixed debt remains.

The second pre-mortem is regulatory rather than cyclical. Suppose that by 2028 PFAS-related rulings, remediation agreements and product restrictions require several hundred million euros of cumulative cash spending, while some fluorinated-material customers accelerate substitution. Group EBITDA settles around EUR 1.1 billion, net debt plus hybrids rises toward EUR 4 billion as cash remediation competes with deleveraging, and investors apply about 5 times EBITDA. Equity value can again fall into the EUR 20s. The specific current lawsuits do not establish such an outcome; they establish a plausible pathway by which a low-probability legal tail could become a balance-sheet issue.

Final research conclusion. Arkema has already accomplished the industrial transformation that many cyclical companies merely promise. What remains is the financial test. Bostik, PA11, PVDF, polyimides and specialty coatings have made the portfolio better, yet 2025's EUR 1.251 billion EBITDA, 2.9-times leverage and weak 2026 volumes show that “85% Specialty Materials” has not yet translated into premium-specialty stability. Q2 delivered real evidence of improvement: margins rose sharply, projects contributed, costs came down and EBITDA beat consensus. What it did not deliver was the missing evidence of a volume recovery.

At EUR 58.05, the shares offer meaningful base-case upside if EBITDA normalizes toward EUR 1.3–1.4 billion and debt begins falling. That same price sits above my conservative-value range, which leaves no margin of safety under the requested discipline. I would therefore require either a materially lower entry price or several quarters of evidence that volume, cash conversion and leverage are healing. The largest analytical mistake would be to capitalize Q2's price effect as permanent; the largest missed opportunity would be to ignore how quickly earnings can rise if the transformed asset base finally receives normal volumes.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: medium
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: cyclical

【Investment rating】

• Rating: Watch
• One-line thesis: Q2 margin recovery is real, but 2.9x leverage and pass-through-heavy pricing leave insufficient downside protection at EUR 58.05.
• Current-price classification: outside the three bands; above the ideal-buy zone and below the acceptable-hold band.
• Whether to wait for a better price: yes. A price of EUR 32–36 with intact operating fundamentals would satisfy the strict conservative-case margin-of-safety test; alternatively, stronger volume and deleveraging could raise intrinsic value enough to justify a higher entry.
• Opportunity cost of waiting: Arkema could rerate before reaching the buy zone if Q3/Q4 establish positive volume growth and leverage declines; the base scenario implies a materially higher fair value than today's price.
• Target holding horizon: 3–5 years.
• Expected annualized return: approximately -1% conservative, +14% base and +29% optimistic over three years, including an unchanged EUR 3.60 annual dividend.
• Max-loss risk: approximately 50–65% in a combined advanced-material utilization downturn, persistent leverage and 5-times-EBITDA derating; PFAS-related cash liabilities provide a second tail-loss path.

【Ideal Buy Price】32–36 EUR Basis: at least about 20% below the roughly EUR 45 midpoint of the conservative valuation scenario, with current specialty franchises intact.

Acceptable hold price: 64–85 EUR, corresponding approximately to ±15% around the EUR 74 base-scenario midpoint.

Clearly overvalued price: 126–135 EUR, beginning more than 10% above the roughly EUR 114 optimistic-scenario midpoint.

Reassessment-trigger signals: organic group volume below -2% for two consecutive quarters; Advanced Materials EBITDA margin below 17.5% for two quarters; net debt plus hybrids above 3.0 times LTM EBITDA after normal seasonal working-capital unwind; 2026 project EBITDA contribution below roughly EUR 35 million; or a material new PFAS/environmental provision that changes annual owner cash flow.

【Valuation Range】

• current: 58.05 EUR (close as of 2026-09-09)
• bear (conservative · ideal buy zone): [32, 36] EUR
• base (fair · acceptable hold zone): [64, 85] EUR
• bull (optimistic · above the clearly-overvalued line): [126, 135] EUR

The margin-of-safety classification and rating deliberately do not track the base-case upside mechanically. Arkema can be undervalued relative to a recovery case while still offering inadequate protection against a no-recovery case. For a leveraged cyclical company, that distinction is especially important.

Research uncertainties are concentrated in five places. First, Arkema does not disclose maintenance versus growth capex, so the owner-earnings calculation relies on a EUR 350–450 million maintenance estimate. Second, I could not verify a clean five-year IFRS CFO/net-income series on a consistent restated perimeter and therefore have not invented the requested ratio. Third, Arkema has not quantified the Q2 Middle East/Performance Additives EBITDA headwind separately; the Advanced Materials decline provides only an outer boundary. Fourth, ultimate PFAS remediation and litigation exposure is unknowable from current claims and should not be confused with regional cleanup estimates. Fifth, I did not use a time-mixed peer-multiple table because comparable September 2026 EV/EBITDA data on identical accounting bases were not available across every peer.

The principal primary sources are Arkema's Q2 2026 results release and financial reconciliation, which establish the sales bridge, segment results, cash flow, leverage and EBITDA definition. Arkema's Q2 investor presentation supplies the cost program, project contributions, capacity start-ups and full-year outlook. The FY2025 results provide the trough-year base and project-performance comparison. Arkema's corporate history and strategy materials establish the 2006–2026 portfolio transformation and technical-platform structure. Arkema's listing, capital and share-price disclosures establish the listing date, current share count, voting rights and September 9 price. External cross-checks include Euronext for current corporate notices, the Financial Times/Cefic for European chemical-industry conditions, Reuters for Sika and Middle East market conditions, and Le Monde for the 2026 Pierre-Bénite PFAS litigation.

Other tickers mentioned

• SIKA.SW: premium formulation and construction-chemicals benchmark for Bostik and Arkema's achievable margin quality.
• SYENS.BR: high-performance specialty-materials reference for Arkema's Advanced Materials portfolio and fluoropolymer competition.
• VCT.LSE: high-performance-polymer pure-play used to benchmark qualification-driven material economics.
• SGO.PA: downstream building-materials reference for construction-cycle demand transmitted into Arkema adhesives and coatings.
• EVK.DE: diversified European specialty-chemicals comparator for cycle exposure, pricing and cost restructuring.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.